Literature DB >> 17876763

Adaptive Dunnett tests for treatment selection.

Franz Koenig1, Werner Brannath, Frank Bretz, Martin Posch.   

Abstract

Clinical trials incorporating treatment selection at pre-specified interim analyses allow to integrate two clinical studies into a single, confirmatory study. In an adaptive interim analysis, treatment arms are selected based on interim data as well as external information. The specific selection rule does not need to be pre-specified in advance in order to control the multiple type I error rate. We propose an adaptive Dunnett test procedure based on the conditional error rate of the single-stage Dunnett test. The adaptive procedure uniformly improves the classical Dunnett test, which is shown to be strictly conservative if treatments are dropped at interim. The adaptive Dunnett test is compared in a simulation with the classical Dunnett test as well as with adaptive combination tests based on the closure principle. The method is illustrated with a real-data example.

Entities:  

Mesh:

Year:  2008        PMID: 17876763     DOI: 10.1002/sim.3048

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  22 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

Review 2.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

3.  Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.

Authors:  Jan Regnstrom; Franz Koenig; Bo Aronsson; Tatiana Reimer; Kristian Svendsen; Stelios Tsigkos; Bruno Flamion; Hans-Georg Eichler; Spiros Vamvakas
Journal:  Eur J Clin Pharmacol       Date:  2009-11-20       Impact factor: 2.953

4.  Response adaptive randomization procedures in seamless phase II/III clinical trials.

Authors:  Hongjian Zhu; Jin Piao; J Jack Lee; Feifang Hu; Lixin Zhang
Journal:  J Biopharm Stat       Date:  2019-08-27       Impact factor: 1.051

5.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

6.  Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs.

Authors:  Anastasia Ivanova; Changfu Xiao
Journal:  Pharm Stat       Date:  2013-07-26       Impact factor: 1.894

7.  Two-stage designs for Phase 2 dose-finding trials.

Authors:  Anastasia Ivanova; Changfu Xiao; Yevgen Tymofyeyev
Journal:  Stat Med       Date:  2012-08-01       Impact factor: 2.373

8.  Adaptive graph-based multiple testing procedures.

Authors:  Florian Klinglmueller; Martin Posch; Franz Koenig
Journal:  Pharm Stat       Date:  2014-10-16       Impact factor: 1.894

9.  Simultaneous confidence intervals that are compatible with closed testing in adaptive designs.

Authors:  D Magirr; T Jaki; M Posch; F Klinglmueller
Journal:  Biometrika       Date:  2013-12-01       Impact factor: 2.445

10.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.